3 completed, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow GV1001 peptide: new trials by email Literature Review of GV1001 peptide trials Research Report on GV1001 peptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD) GV1001, Normal saline - Moderate Alzheimer's Disease | Phase 2 | Withdrawn | GemVax & Kael | 2019-09-01 | 2022-03-03 | |
| A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH Placebo, GV1001 - Benign Prostatic Hyperplasia (BPH) | Phase 2 | Completed | GemVax & Kael | 161 | 2015-10-01 | 2022-03-04 |
| A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma. GV1001 - Carcinoma, Hepatocellular | Phase 2 | Completed | Pharmexa A/S | 41 | 2006-11-01 | 2008-12-18 |
| Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma GV1001 - Malignant Melanoma | Phase 1 / Phase 2 | Completed | Oslo University Hospital | 2005-01-01 | 2014-11-05 |
Alzheimer Disease (1) · Carcinoma, Hepatocellular (1) · Melanoma (1) · Prostatic Hyperplasia (1)
GemVax & Kael (2) · Oslo University Hospital (1) · Pharmexa A/S (1)
France (1) · Germany (1) · Norway (1) · South Korea (1) · Spain (1)
Kyung Seop Lee (1) · Lotte Rosendahl, Pharmacist (CTM) (1)